Market Closed -
Nasdaq
01:30:00 03/05/2024 am IST
|
5-day change
|
1st Jan Change
|
937.6
USD
|
+3.78%
|
|
+5.27%
|
+6.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
41,049
|
50,990
|
66,029
|
77,057
|
93,403
|
1,01,155
|
-
|
-
|
Enterprise Value (EV)
1 |
35,291
|
50,098
|
56,196
|
77,057
|
84,542
|
92,662
|
88,676
|
83,857
|
P/E ratio
|
20.3
x
|
15.8
x
|
8.77
x
|
18.9
x
|
25.3
x
|
27.2
x
|
24.4
x
|
20.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.22
x
|
6
x
|
4.11
x
|
6.33
x
|
7.12
x
|
7.3
x
|
6.82
x
|
6.34
x
|
EV / Revenue
|
4.49
x
|
5.9
x
|
3.5
x
|
6.33
x
|
6.45
x
|
6.68
x
|
5.98
x
|
5.25
x
|
EV / EBITDA
|
10.3
x
|
11.8
x
|
5.71
x
|
12.7
x
|
15.2
x
|
15
x
|
14.6
x
|
12.5
x
|
EV / FCF
|
17.6
x
|
25
x
|
8.61
x
|
17.4
x
|
21.8
x
|
18.8
x
|
18
x
|
15.1
x
|
FCF Yield
|
5.67%
|
4%
|
11.6%
|
5.74%
|
4.58%
|
5.33%
|
5.55%
|
6.61%
|
Price to Book
|
3.7
x
|
4.71
x
|
3.56
x
|
3.41
x
|
3.64
x
|
3.37
x
|
2.97
x
|
2.54
x
|
Nbr of stocks (in thousands)
|
1,09,323
|
1,05,544
|
1,04,556
|
1,06,802
|
1,06,347
|
1,07,886
|
-
|
-
|
Reference price
2 |
375.5
|
483.1
|
631.5
|
721.5
|
878.3
|
937.6
|
937.6
|
937.6
|
Announcement Date
|
06/02/20
|
05/02/21
|
04/02/22
|
03/02/23
|
02/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
7,863
|
8,497
|
16,072
|
12,173
|
13,117
|
13,866
|
14,841
|
15,962
|
EBITDA
1 |
3,420
|
4,244
|
9,835
|
6,060
|
5,547
|
6,180
|
6,089
|
6,727
|
EBIT
1 |
2,210
|
3,577
|
8,947
|
5,719
|
5,126
|
5,206
|
5,612
|
6,206
|
Operating Margin
|
28.1%
|
42.09%
|
55.67%
|
46.98%
|
39.08%
|
37.55%
|
37.81%
|
38.88%
|
Earnings before Tax (EBT)
1 |
2,429
|
3,810
|
9,326
|
4,859
|
4,199
|
4,269
|
4,850
|
5,438
|
Net income
1 |
2,116
|
3,513
|
8,075
|
4,338
|
3,954
|
3,760
|
4,454
|
5,231
|
Net margin
|
26.91%
|
41.35%
|
50.25%
|
35.64%
|
30.14%
|
27.12%
|
30.01%
|
32.77%
|
EPS
2 |
18.46
|
30.52
|
71.97
|
38.22
|
34.77
|
34.48
|
38.35
|
45.34
|
Free Cash Flow
1 |
2,000
|
2,004
|
6,529
|
4,425
|
3,875
|
4,938
|
4,924
|
5,541
|
FCF margin
|
25.44%
|
23.58%
|
40.63%
|
36.35%
|
29.54%
|
35.61%
|
33.18%
|
34.71%
|
FCF Conversion (EBITDA)
|
58.5%
|
47.2%
|
66.39%
|
73.01%
|
69.86%
|
79.9%
|
80.87%
|
82.37%
|
FCF Conversion (Net income)
|
94.55%
|
57.03%
|
80.86%
|
101.99%
|
98.02%
|
131.32%
|
110.55%
|
105.93%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/02/20
|
05/02/21
|
04/02/22
|
03/02/23
|
02/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
3,453
|
4,952
|
2,965
|
2,857
|
2,936
|
3,414
|
3,162
|
3,158
|
3,363
|
3,434
|
3,145
|
3,397
|
3,566
|
3,732
|
3,577
|
EBITDA
1 |
2,057
|
2,903
|
1,558
|
1,344
|
1,488
|
1,637
|
1,315
|
1,351
|
1,488
|
1,395
|
1,195
|
1,292
|
1,419
|
1,512
|
1,290
|
EBIT
1 |
1,847
|
2,640
|
1,483
|
1,285
|
1,413
|
1,537
|
1,215
|
1,248
|
1,382
|
1,282
|
1,028
|
1,227
|
1,376
|
1,418
|
1,420
|
Operating Margin
|
53.5%
|
53.31%
|
50.03%
|
44.99%
|
48.12%
|
45.02%
|
38.43%
|
39.51%
|
41.11%
|
37.33%
|
32.68%
|
36.13%
|
38.58%
|
38%
|
39.69%
|
Earnings before Tax (EBT)
1 |
1,817
|
2,503
|
1,061
|
963.2
|
1,510
|
1,325
|
858
|
1,083
|
1,111
|
1,148
|
700.7
|
1,160
|
1,171
|
1,227
|
-
|
Net income
1 |
1,632
|
2,229
|
973.5
|
852.1
|
1,316
|
1,197
|
817.8
|
968.4
|
1,008
|
1,160
|
722
|
991.3
|
1,055
|
1,111
|
-
|
Net margin
|
47.27%
|
45.01%
|
32.83%
|
29.82%
|
44.81%
|
35.06%
|
25.86%
|
30.66%
|
29.97%
|
33.77%
|
22.96%
|
29.18%
|
29.58%
|
29.77%
|
-
|
EPS
2 |
14.33
|
19.69
|
8.610
|
7.470
|
11.66
|
10.50
|
7.170
|
8.500
|
8.890
|
10.19
|
6.270
|
8.609
|
9.348
|
9.616
|
10.53
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
04/02/22
|
04/05/22
|
03/08/22
|
03/11/22
|
03/02/23
|
04/05/23
|
03/08/23
|
02/11/23
|
02/02/24
|
02/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5,757
|
891
|
9,833
|
-
|
8,862
|
8,492
|
12,479
|
17,298
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2,000
|
2,004
|
6,529
|
4,425
|
3,875
|
4,938
|
4,924
|
5,541
|
ROE (net income / shareholders' equity)
|
28.5%
|
33.2%
|
54.2%
|
24.9%
|
20.7%
|
18.4%
|
17.3%
|
16.7%
|
ROA (Net income/ Total Assets)
|
15.9%
|
22%
|
37.9%
|
18.9%
|
16.2%
|
14%
|
11.9%
|
12.5%
|
Assets
1 |
13,270
|
15,984
|
21,299
|
22,956
|
24,412
|
26,859
|
37,473
|
41,809
|
Book Value Per Share
2 |
102.0
|
102.0
|
178.0
|
212.0
|
241.0
|
278.0
|
316.0
|
369.0
|
Cash Flow per Share
2 |
21.20
|
22.70
|
63.10
|
44.20
|
40.40
|
49.00
|
49.90
|
55.40
|
Capex
1 |
430
|
615
|
552
|
590
|
719
|
776
|
766
|
776
|
Capex / Sales
|
5.46%
|
7.23%
|
3.43%
|
4.85%
|
5.48%
|
5.6%
|
5.16%
|
4.86%
|
Announcement Date
|
06/02/20
|
05/02/21
|
04/02/22
|
03/02/23
|
02/02/24
|
-
|
-
|
-
|
Last Close Price
937.6
USD Average target price
1,040
USD Spread / Average Target +10.89% Consensus |
1st Jan change
|
Capi.
|
---|
| +6.75% | 101B | | -1.65% | 103B | | +6.75% | 23.07B | | -12.60% | 22.23B | | -5.01% | 18.05B | | -39.98% | 17.18B | | -10.17% | 16.94B | | +6.12% | 14.07B | | +35.47% | 12.35B | | -23.67% | 8.36B |
Bio Therapeutic Drugs
|